RESEARCH 研究の報告

2024.9.3

Prognostic significance of LAT1 expression in pleural mesothelioma.

著者 Taguchi R, Kaira K, Miura Y, Umesaki T, Mouri A, Imai H, Kagamu H, Yasuda M, Kanai Y, Nitanda H, Ishida H, Sakaguchi H.

Heliyon. 2024 Sep 3;10(17):e37414. doi: 10.1016/j.heliyon.2024.e37414. eCollection 2024 Sep 15.

PMID: 39290273 Free PMC article.

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161 Free PMC article. Review.

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.

PMID: 39102792

2024.7.3

Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.

著者 Ito K, Kaira K, Imai H, Shiono A, Hashimoto K, Yamaguchi OU, Kagamu H.

Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.

PMID: 38962554 Free PMC article.

2024.7.1

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.

著者 Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H.

Curr Oncol Rep. 2024 Sep;26(9):1113-1119. doi: 10.1007/s11912-024-01571-0. Epub 2024 Jul 1.

PMID: 38954314 Review.

2024.5.31

Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review.

著者 Kaira K, Ichiki Y, Imai H, Kawasaki T, Hashimoto K, Kuji I, Kagamu H.

Transl Lung Cancer Res. 2024 May 31;13(5):1137-1149. doi: 10.21037/tlcr-24-142. Epub 2024 May 24.

PMID: 38854945 Free PMC article. Review.

2024.5.31

Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma.

著者 Kaira K, Imai H, Kagamu H.

Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.

PMID: 38854932 Free PMC article. No abstract available.

2024.5.16

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.

著者 Wasamoto S, Imai H, Tsuda T, Nagai Y, Kishikawa T, Ono A, Masubuchi K, Umeda Y, Yamada Y, Nakagawa J, Yui T, Taniguchi H, Kaira K, Kagamu H.

Intern Med. 2024 May 16. doi: 10.2169/internalmedicine.3649-24. Online ahead of print.

PMID: 38749728 Free article.

2023.8.29

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

著者 Hisao Imai,　Satoshi Wasamoto,　Takeshi Tsuda,　Yoshiaki Nagai,　Takayuki Kishikawa,　Ken Masubuchi,　Takashi Osaki,　Yosuke Miura,　Yukihiro Umeda,　Akihiro Ono,　Hiroyuki Minemura,　Yutaka Yamada,　Junichi Nakagawa,　Yuki Kozu,　Hirokazu Taniguchi,　Hiromitsu Ohta,　Takashi Kasai,　Kyoichi Kaira,　Hiroshi Kagamu.

Thorac Cancer . 2023 Sep;14(25):2567-2578. doi: 10.1111/1759-7714.15036. Epub 2023 Jul 19.

PMID: 37469246 PMCID: PMC10481141 DOI: 10.1111/1759-7714.15036

2023.5.8

Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.

著者 Ito K,　Yamaguchi O,　Kaira K,　Imai H,　Kagamu H.

Lung Cancer . 2023 May:179:107193. doi: 10.1016/j.lungcan.2023.107193. Epub 2023 Apr 10.

PMID: 37058785 DOI: 10.1016/j.lungcan.2023.107193